BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35292921)

  • 1. Comparison of the Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants with Warfarin in Atrial Fibrillation Patients with a History of Bleeding: A Systematic Review and Meta-Analysis.
    Suah BH; Lee ZY; Teo YH; Teo YN; Syn NLX; Soh RYH; Yeo LLL; Tan BYQ; Ho JS; Li TYW; Lee CH; Chan MY; Yeo TC; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):511-521. PubMed ID: 35292921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis.
    Barbarawi M; Barbarawi O; Corcoran J; Obeidat K; Al-Abdouh A; Mhanna M; Al Kasasbeh M; Pickett CC
    Curr Probl Cardiol; 2022 Nov; 47(11):101346. PubMed ID: 35932849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.
    Patel SM; Braunwald E; Steffel J; Boriani G; Palazzolo MG; Antman EM; Bohula EA; Carnicelli AP; Connolly SJ; Eikelboom JW; Gencer B; Granger CB; Morrow DA; Patel MR; Wallentin L; Ruff CT; Giugliano RP;
    Circulation; 2024 Mar; 149(12):932-943. PubMed ID: 38264923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
    Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
    J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.
    Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Stroke; 2020 Feb; 51(2):416-423. PubMed ID: 31813363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.
    Lee HJ; Kim HK; Jung JH; Han KD; Lee H; Park JB; Kim HM; Kim YJ; Ommen SR
    Stroke; 2019 Sep; 50(9):2582-2586. PubMed ID: 31340730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis.
    Li Z; Zheng Y; Li D; Wang X; Cheng S; Luo X; Wen A
    Anatol J Cardiol; 2022 Jun; 26(6):424-433. PubMed ID: 35703478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients (≥80 years of age) with atrial fibrillation: systematic review and meta-analysis.
    Kang F; Su L; Fan S; Lv L; Luo B
    Intern Med J; 2023 Sep; 53(9):1524-1532. PubMed ID: 37178051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Previous Stroke: A Systematic Review and Meta-Analysis.
    Shi M; Liu L; Wafa H; Curcin V; Wang Y
    Neuroepidemiology; 2024; 58(1):1-14. PubMed ID: 37848006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and safety of non-vitamin-K antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes.
    Korgaonkar S; Yang Y; Banahan B; Bentley JP
    Curr Med Res Opin; 2021 Mar; 37(3):343-356. PubMed ID: 33327796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review.
    Fu Y; Zhu W; Zhou Y; Chen H; Yan L; He W
    Am J Cardiovasc Drugs; 2020 Apr; 20(2):139-147. PubMed ID: 31485852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
    Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY
    Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
    Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies.
    Guo Z; Ding X; Ye Z; Chen W; Chen Y
    Clin Cardiol; 2021 Jul; 44(7):917-924. PubMed ID: 34013988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.